DEA Quadruples Psilocybin Manufacturing for Research in Final 2021 Production Quotas
Drug Enforcement Agency also hugely boosts MDMA and DMT quotas “in response to the nationwide public interest in hallucinogenic controlled substances research.”
Emily Jarvie is a freelance journalist reporting on business and scientific developments in the evolving psychedelics space. Her work has appeared in North American, Australian, and European publications.
Drug Enforcement Agency also hugely boosts MDMA and DMT quotas “in response to the nationwide public interest in hallucinogenic controlled substances research.”
This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.
And the results, according to the participants, were nothing short of “profound.”
Rick Doblin’s organization partners with Numinus Wellness to manage the Canadian sites where therapists will be administering the psychedelic therapy.
“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,” explains principal investigator Dr. David J. Hellerstein, who was evaluating Compass Pathways’ novel drug formulation COMP360.
Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration of effect, and improved brain penetration.
This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
This trial, using Filament Health’s botanical drug candidates, is the first to assess the direct administration of psilocin.
As the decriminalization movement sweeps through Michigan, Detroit becomes the largest city in the state to decriminalize entheogenic plants.
Pop star says in new interview that tripping on psilocybin enabled him, for the first time, to “write actual stories about my life and put it into my music.”
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.